Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-25T08:09:02.993Z Has data issue: false hasContentIssue false
  • English
  • Français

Visual hallucinations in consultation-liaison neuropsychiatry

Published online by Cambridge University Press:  24 June 2014

Mark Walterfang ,
Ramon Mocellin  and
Dennis Velakoulis
Mark Walterfang*
Affiliation:
Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia
Ramon Mocellin
Affiliation:
Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia
Dennis Velakoulis
Affiliation:
Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia
*
Dr Mark Walterfang, Neuropsychiatry Unit, Level 2, John Cade Building, Royal Melbourne Hospital, Parkville 3050, Victoria, Australia. Tel: +61 3 93428750; Fax: +61 3 93428483; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

In consultation-liaison settings, neuropsychiatrists are commonly asked to assess patients with hallucinatory syndromes and to differentiate ‘functional’ from ‘organic’ psychotic presentations.

Methods:

The occurrence and management of visual hallucinations (VH) in healthy individuals, lesion states, neurodegenerative disorders, intoxication/withdrawal states and delirium are reviewed.

Results:

The presence of VH has been shown to predict a secondary rather than primary psychotic illness and an understanding of the neurobiology of the visual system – including how and where underlying neurotransmitter systems interact in visual processing and how perturbations can result in VH – allows for appropriate clinical assessment and management.

Keywords

deliriumdopaminehallucinationshallucinosisvisual
Type
Review article
Information
Acta Neuropsychiatrica , Volume 19 , Issue 6 , December 2007 , pp. 330 - 337
Copyright
Copyright © 2007 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fox, H. The DSM-III concept of organic brain syndrome. Br J Psychiatry 1983;142:419–421. CrossRefGoogle ScholarPubMed
Spitzer, R, First, M, Williams, J, Kendler, K, Pincus, H, Tucker, G. Now is the time to retire the term ‘organic mental disorders’. Am J Psychiatry 1992;149:240–244. Google Scholar
Davison, K, Bagley, C. Schizophrenia-like psychoses associated with organic disorder of the central nervous system: a review of the literature. Br J Psychiatry 1969;113 (Suppl. 1):18–69. Google Scholar
Cutting, J. The phenomenology of acute organic psychosis. Comparison with acute schizophrenia. Br J Psychiatry 1987;151:324–332. CrossRefGoogle ScholarPubMed
Johnstone, E, Cooling, N, Frith, C, Crow, T, Owens, D. Phenomenology of organic and functional psychoses and the overlap between them. Br J Psychiatry 1988;153:770–776. CrossRefGoogle Scholar
Feinstein, A, Ron, M. Psychosis associated with demonstrable brain disease. Psychol Med 1990;20:793–803. CrossRefGoogle ScholarPubMed
Asaad, G, Shapiro, B. Hallucinations: theoretical and clinical overview. Am J Psychiatry 1986;143:1088–1097. Google ScholarPubMed
Sarbin, T, Juhasz, J. The social context of hallucinations. In: Siegel, R, West, L, eds. Hallucinations: behavior, experience and theory. New York: John Wiley & Sons, 1975:241–256. Google Scholar
Johns, L. Hallucinations in the general population. Curr Psychiatry Rep 2005;7:162–167. CrossRefGoogle ScholarPubMed
Serper, M, Dill, CA, Chang, N, Kot, T, Elliot, J. Factorial structure of the hallucinatory experience: continuity of experience in psychotic and normal individuals. J Nerv Ment Dis 2005;193:265–272. CrossRefGoogle ScholarPubMed
Levine, E, Jonas, H, Serper, M. Interpersonal attributional biases in hallucinatory-prone individuals. Schizophr Res 2004;69:23–28. CrossRefGoogle ScholarPubMed
Laroi, F, Collignon, O, Van der Linden, M. Source monitoring for actions in hallucination proneness. Cognit Neuropsychiatry 2005;10:105–123. Google ScholarPubMed
Aleman, A, Nieuwenstein, M, Bocker, K, De Haan, E. Mental imagery and perception in hallucination-prone individuals. J Nerv Ment Dis 2000;188:830–836. CrossRefGoogle ScholarPubMed
Morrison, A, Wells, A, Nothard, S. Cognitive factors in predisposition to auditory and visual hallucinations. Br J Clin Psychol 2000;39:67–78. CrossRefGoogle ScholarPubMed
Tien, A. Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol 1991;26:287–292. CrossRefGoogle ScholarPubMed
Lindal, E, Stefansson, J, Stefansson, S. The qualitative difference of visions and visual hallucinations: a comparison of a general-population and clinical sample. Compr Psychiatry 1994;35:405–408. CrossRefGoogle ScholarPubMed
LaBarre, W. Anthropological perspectives on hallucination and hallucinogens. In: Siegel, R, West, C, eds. Hallucinations: behaviour, experience and theory. New York: John Wiley & Sons, 1975:9–52. Google Scholar
Ohayon, M. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000;97:153–164. CrossRefGoogle ScholarPubMed
Ohayon, M, Priest, R, Caulet, M, Guilleminault, C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry 1996;169:459–467. CrossRefGoogle ScholarPubMed
Hurlock, E, Burnstein, M. The imaginary playmate: a questionnaire study. J Genet Psychol 1932;41:380–392. Google Scholar
Svendsen, M. Children’s imaginary companions. Arch Neurol Psychiatry 1934;12:985–989. CrossRefGoogle Scholar
Schaeffer, C. Imaginary companions and creative adolescents. Dev Psychol 1969;1:747–749. CrossRefGoogle Scholar
Bonne, O, Canetti, L, Bachar, E, Kaplan De-Nour, A, Shalev, A. Childhood imaginary companionship and mental health in adolescence. Child Psychiatry Hum Dev 1999;29:277–286. CrossRefGoogle ScholarPubMed
Simonds, J. Hallucinations in nonpsychotic children and adolescents. J Youth Adolesc 1975;4:171–182. CrossRefGoogle ScholarPubMed
Balk, D. Adolescents’ grief reactions and self-concept perceptions following sibling death: a study of 33 teenagers. J Youth Adolesc 1983;12:137–161. CrossRefGoogle ScholarPubMed
Adair, D, Keshavan, M. The Charles Bonnet syndrome and grief reaction. Am J Psychiatry 1988;145:895. Google ScholarPubMed
Olson, P, Suddeth, J, Peterson, P. Hallucinations of widowhood. J Am Geriatr Soc 1985;33:543–547. CrossRefGoogle ScholarPubMed
Grimby, A. Bereavement among elderly people: grief reactions, post-bereavement hallucinations and quality of life. Acta Psychiatr Scand 1993;87:72–80. CrossRefGoogle ScholarPubMed
Mullaney, D, Kripke, D, Fleck, P, Johnson, L. Effects of sustained continuous performance on subjects working alone and in pairs. Percept Mot Skills 1983;57:819–832. CrossRefGoogle Scholar
Mullaney, D, Kripke, D, Fleck, P, Johnson, L. Sleep loss and nap effects on sustained continuous performance. Psychophysiology 1983;20:643–651. CrossRefGoogle ScholarPubMed
Forrer, G. Benign auditory and visual hallucinations. Arch Gen Psychiatry 1964;3:95–98. CrossRefGoogle ScholarPubMed
Walsh, F, Hoyt, W. Clinical neuo-ophthalmology, 3rd edn. Baltimore: Williams & Wilkins, 1969. Google Scholar
Cummings, J, Miller, B. Visual hallucinations: clinical occurrence and use in differential diagnosis. West J Med 1987;146:46–51. Google ScholarPubMed
Penfield, W, Perot, P. The brain’s record of auditory and visual experience: a final summary and discussion. Brain 1963;86:595–696. CrossRefGoogle ScholarPubMed
West, C. Hallucinations. New York: Grune & Stratton, 1962. Google Scholar
Cogan, D. Visual hallucinations as release phenomena. Graefes Arch Clin Exp Ophthalmol 1973;188:139–150. CrossRefGoogle ScholarPubMed
Mocellin, R, Walterfang, M, Velakoulis, D. The neuropsychiatry of complex visual hallucinations. Aust N Z J Psychiatry 2006;40:742–751. CrossRefGoogle ScholarPubMed
Manford, M, Andermann, F. Complex visual hallucinations: clinical and neurobiological insights. Brain 1998;121:1819–1840. CrossRefGoogle ScholarPubMed
Santhouse, A, Howard, R, Ffytche, D. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 2000;123:2055–2064. CrossRefGoogle ScholarPubMed
Ffytche, D, Howard, R. The perceptual consequences of visual loss: ‘positive’ pathologies of vision. Brain 1999;122:1247–1260. CrossRefGoogle Scholar
Ffytche, D, Howard, R, Brammer, M, David, A, Woodruff, P, Williams, S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci 1998;1:738–742. CrossRefGoogle ScholarPubMed
Howard, R, David, A, Woodruff, P, Mellers, I, Wright, J, Brammer, M. Seeing visual hallucinations with functional magnetic resonance imaging. Dement Geriatr Cogn Disord 1997;8:73–77. CrossRefGoogle ScholarPubMed
Lepore, F. Spontaneous visual phenomena with visual loss: 104 patients with lesions of retinal and neural afferent pathways. Neurology 1990;40:444–447. CrossRefGoogle ScholarPubMed
Galasko, D, Kwo-On-Yuen, P, Thal, L. Intracranial mass lesions associated with late-onset psychosis and depression. Psychiatr Clin North Am 1988;11:151–166. Google ScholarPubMed
Perry, E, Perry, R. Acetylcholine and hallucinations: disease related compared to drug-induced alterations in human consciousness. Brain Cogn 1995;28:240–258. CrossRefGoogle ScholarPubMed
Perry, E, Johnson, M, Kerwin, Jet al. Convergent cholinergic activities in aging and Alzheimer’s disease. Neurobiol Aging 1992;13:393–400. CrossRefGoogle ScholarPubMed
Glennon, R, Titeler, M, McKenney, J. Evidence for 5HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35:2505–2511. CrossRefGoogle Scholar
Abraham, H, Aldridge, A, Gogia, P. The psychopharmacology of hallucinogens. Neuropsychopharmacol 1996;14:285–298. CrossRefGoogle ScholarPubMed
Goetz, C, Vogel, C, Tanner, C, Stebbins, G. Early dopaminergic drug induced hallucinations in Parkinsonian patients. Neurology 1998;51:811–814. CrossRefGoogle ScholarPubMed
Angrist, B, Sathananthan, G, Wilk, S, Gershon, S. Amphetamine psychosis: behavioural and biochemical aspects. J Psychiatr Res 1974;11:13–23. CrossRefGoogle ScholarPubMed
Dubois, B, Danze, F, Pillon, B, Cusimano, G, Lhermitte, F, Agid, Y. Cholinergic dependent cognitive deficits in Parkinson’s disease. Ann Neurol 1987;22:26–30. CrossRefGoogle ScholarPubMed
Perry, E, Marshall, E, Kerwin, J, Smith, C, Jabeen, S, Cheng, A. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1991;55:1454–1456. CrossRefGoogle ScholarPubMed
Packard, R. Delirium. Neurologist 2001;7:327–340. CrossRefGoogle ScholarPubMed
Brown, T. Basic mechanisms in the pathogenesis of delirium. In: Stoudemire, A, Fogel, B, Greenberg, D, eds. Psychiatric care of the medical patient. New York: Oxford University Press, 2000: 571–580. Google Scholar
Nevo, I, Hamon, M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995;26:305–336. CrossRefGoogle ScholarPubMed
Collerton, D, Perry, E, McKeith, I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005;28:737–794. CrossRefGoogle Scholar
Ffytche, D. Visual hallucination and illusion disorders: a clinical guide. Adv Clin Neurosci Rehab 2004;4:16–18. Google Scholar
Kawai, M, Cherches, I, Goldsmith, I. Visual illusory and hallucinatory phenomena in a patient with left occipital seizures. Neurology 2006;67:1457. CrossRefGoogle Scholar
Braun, C, Dumont, M, Duval, J, Hamel-Hebert, I, Godbout, L. Brain modules of hallucination: an analysis of multiple patients with brain lesions. J Psychiatry Neurosci 2003;28:432–439. Google ScholarPubMed
Teunisse, R, Cruysberg, J, Hoefnagels, W, Verbeek, A, Zitmans, F. Visual hallucinations in psychologically normal people: Charles Bonnet’s syndrome. Lancet 1996;347:794–797. CrossRefGoogle ScholarPubMed
Bonnet, C. Essai Analytique Sur les Facultés de L’âme, 2nd edn. Copenhague, 1769. Google Scholar
Holroyd, S, Shepherd, M, Downs, J. Occipital atrophy is associated with visual hallucinations in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2000;12:25–28. CrossRefGoogle ScholarPubMed
Lhermitte, M. Syndrome de la calotte due penduncule cerebral. Les troubels psycho-sensoriels dans les lesions du mesocephale. Revue de Neurologique (Paris) 1922;38:1359–1365. Google Scholar
Bassiony, M, Lyketsos, C. Delusions and hallucinations in Alzheimer’s disease: review of the brain decade. Psychosomatics 2003;44:388–401. CrossRefGoogle ScholarPubMed
Lin, S, Yu, C, Pai, M. The occipital white matter lesions in Alzheimer’s disease patients with visual hallucinations. Clin Imaging 2006;30:388–393. CrossRefGoogle ScholarPubMed
Josephs, Ket al. Visual hallucinations in posterior cortical atrophy. Arch Neurol 2006;63:1427–1432. CrossRefGoogle ScholarPubMed
Lewis, D, Campbell, M, Terry, R, Morrison, JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer’s disease: a quantitative study of visual and auditory cortices. J Neurosci 1987;7:1799–1808. Google ScholarPubMed
Foerster, O. The cerebral cortex in man. Lancet 1931;2:309–319. Google Scholar
Chapman, F, Dickinson, J, McKeith, I, Ballard, C. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer’s disease: treatment implications. Am J Psychiatry 1999;156:1983–1985. Google ScholarPubMed
Barnes, J, David, A. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727–733. CrossRefGoogle ScholarPubMed
Mosimann, M, Mather, G, Wesnes, K, O’Brien, J, Burn, D, McKeith, I. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091–2096. CrossRefGoogle ScholarPubMed
Bohnen, N, Kaufer, D, Ivanco, Let al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol Psychiatry 2003;60:1745–1748. CrossRefGoogle Scholar
Harding, A, Broe, G, Halliday, G. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391–403. CrossRefGoogle ScholarPubMed
Halliday, G, Blumbergs, P, Cotton, R, Blessing, W, Geffen, L. Loss of brainstem and serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res 1990;510:104–107. CrossRefGoogle ScholarPubMed
Jellinger, K. New developments in the pathology of Parkinson’s disease. Adv Neurol 1990;53:1–16. Google ScholarPubMed
Bodis-Wollner, I, Tagliati, M. The visual system in Parkinson’s disease. Adv Neurol 1993;60:390–394. Google ScholarPubMed
Matsui, Het al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord 2006;21:2140–2144. CrossRefGoogle ScholarPubMed
Holroyd, S, Wooten, G. Preliminary FMRI evidence of visual system dysfunction in Parkinson’s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci 2006;18:402–404. CrossRefGoogle ScholarPubMed
Collerton, D, Burn, D, McKeith, I, O’Brien, J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003;16:229–237. CrossRefGoogle ScholarPubMed
Young, B. A phenomenological comparison of LSD and schizophrenic states. Br J Psychiatry 1974;124:64–74. CrossRefGoogle ScholarPubMed
Marek, G, Wright, R, Gewirtz, J, Schoepp, D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 2001;105:379–392. CrossRefGoogle Scholar
Aghajanian, G, Marek, G. Serotonin and hallucinogens. Neuropsychopharmacol 1999;21:S16–S23. CrossRefGoogle ScholarPubMed
Sarter, M, Bruno, J. Cortical acetylcholine, reality distortion, schizophrenia and Lewy body dementia: too much or too little acetylcholine? Brain Cogn 1998;38:297–316. CrossRefGoogle ScholarPubMed
Cancelli, I, Marcon, G, Balestrieri, M. Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol 2004;19:577–584. CrossRefGoogle ScholarPubMed
Moore, H, Fadel, J, Sarter, M, Bruno, J. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience 1998;88:811–822. CrossRefGoogle ScholarPubMed
Lipowski, Z. Delirium due to alcohol and drug withdrawal. In: Lipowski, Z, ed. Delirium: acute brain failure in man. Springfield: Charles C Thomas, 1980: 317–343. Google Scholar
MacKinnon, G, Parker, W. Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse 1982;9:19–33. CrossRefGoogle ScholarPubMed
Dyer, J, Roth, B, Hyma, B. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37:147–153. CrossRefGoogle ScholarPubMed
Krystal, J, Staley, J, Mason, Get al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry 2006;63:957–968. CrossRefGoogle ScholarPubMed
Malcolm, R. GABA systems, benzodiazepines, and substance dependence. J Clin Psychiatry 2003;64(Suppl. 3):36–40. Google ScholarPubMed
Faingold, C, N’Gouemo, P, Riaz, A. Ethanol and neurotransmitter interactions–from molecular to integrative effects. Prog Neurobiol 1998;55:509–535. CrossRefGoogle ScholarPubMed
Eysel, U, Schweigart, G, Mittman, Tet al. Reorganization in the visual cortex after retinal and cortical damage. Restor Neurol Neurosci 1999;15:153–164. Google ScholarPubMed
Burke, W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry 2002;73:535–541. CrossRefGoogle ScholarPubMed
Paulig, M, Mentrup, H. Charles Bonnet’s syndrome: complete remission of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry 2001;70:813–814. CrossRefGoogle ScholarPubMed
Gibson, K, Gupta, M, Pearl, Pet al. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol Psychiatry 2003;54:763–768. CrossRefGoogle Scholar
Flacker, J, Lipsitz, L. Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol 1999;54:8239–8246. CrossRefGoogle ScholarPubMed
van der Mast, R. Pathophysiology of delirium. J Geriatr Psychiatry Neurol 1998;11:138–145. CrossRefGoogle ScholarPubMed
Trzepacz, P. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000;5:132–148. Google Scholar
Cowen, M, Lawrence, A. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:1171–1212. CrossRefGoogle ScholarPubMed
Piazza, P, Le Moal, M. Glucocorticoids as a substrate of reward: physiological and pathophysiological implications. Brain Res Brain Res Rev 1997;23:359–372. CrossRefGoogle Scholar
Gaudreau, J, Gagnon, P. Psychogenic drugs and delirium pathogenesis: the central role of the thalamus. Med Hypotheses 2005;64:471–475. CrossRefGoogle Scholar
Freeman, G, Mykytyn, V, Gibson, G. Differential alteration of dopamine, acetylcholine and glutamate release during anoxia and/or 3,4-diaminopyridine treatment. Neurochem Res 1987;12:1019–1027. CrossRefGoogle ScholarPubMed
Gibson, G, Blass, J, Huang, H-M, Freeman, G. The cellular basis of delirium and its relevance to age-related disorders including Alzheimer’s disease. Int Psychogeriatr 1991;3:373–395. CrossRefGoogle ScholarPubMed
Lacasse, H, Perreault, M, Williamson, D. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother 2006;40:1966–1973. CrossRefGoogle ScholarPubMed
Lang, Uet al. Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol 2007 (in press).CrossRefGoogle ScholarPubMed
Koethe, Det al. Cessation of complex visual hallucinations during treatment with mirtazapine. Pharmacopsychiatry 2007;40:82–83. CrossRefGoogle ScholarPubMed